A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.

ATP Binding Cassette Transporter, Subfamily B / genetics ATP Binding Cassette Transporter, Subfamily G, Member 2 / genetics ATP-Binding Cassette Transporters / genetics Adult Aged Carboxylic Ester Hydrolases / genetics Cytochrome P-450 Enzyme System / genetics Diabetes Mellitus, Type 2 / genetics Duodenum / metabolism Female Gene Expression Regulation Humans Male Middle Aged Neoplasm Proteins / genetics Organic Anion Transporters / genetics Pilot Projects RNA, Messenger / genetics
cytochromes P450 drug metabolism intestine type II diabetes mellitus

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Jul 2019
Historique:
received: 02 05 2019
revised: 13 06 2019
accepted: 21 06 2019
entrez: 5 7 2019
pubmed: 5 7 2019
medline: 7 1 2020
Statut: epublish

Résumé

To characterize effects of type 2 diabetes (T2D) on mRNA expression levels for 10 Cytochromes P450 (CYP450s), two carboxylesterases, and three drug transporters (ABCB1, ABCG2, SLCO2B1) in human duodenal biopsies. To compare drug metabolizing enzyme activities of four CYP450 isoenzymes in duodenal biopsies from patients with or without T2D. mRNA levels were quantified (RT-qPCR) in human duodenal biopsies obtained from patients with (

Identifiants

DOI: 10.3390/ijms20133257 PMID: 31269743 PMC: PMC6651059
pubmed: 31269743
pii: ijms20133257
doi: 10.3390/ijms20133257
pmc: PMC6651059
pii:
doi:

Substances chimiques

ABCB1 protein, human 0
ABCG2 protein, human 0
ATP Binding Cassette Transporter, Subfamily B 0
ATP Binding Cassette Transporter, Subfamily G, Member 2 0
ATP-Binding Cassette Transporters 0
Neoplasm Proteins 0
Organic Anion Transporters 0
RNA, Messenger 0
SLCO2B1 protein, human 0
Cytochrome P-450 Enzyme System 9035-51-2
Carboxylic Ester Hydrolases EC 3.1.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Canadian Institutes of Health Research
ID : 299309
Pays : Canada

Références

Drug Metab Dispos. 1999 Jul;27(7):804-9
pubmed: 10383924
Drug Metab Dispos. 2001 Mar;29(3):207-12
pubmed: 11181485
Drug Metab Dispos. 2001 Mar;29(3):347-52
pubmed: 11181505
Xenobiotica. 2001 Apr;31(4):223-37
pubmed: 11465407
J Pharmacol Exp Ther. 2002 Jan;300(1):298-304
pubmed: 11752129
Drug Metab Dispos. 2002 May;30(5):488-93
pubmed: 11950776
Annu Rev Pharmacol Toxicol. 2003;43:149-73
pubmed: 12171978
Drug Metab Dispos. 2002 Nov;30(11):1240-5
pubmed: 12386130
Br J Clin Pharmacol. 2003 Jan;55(1):77-85
pubmed: 12534643
Eur J Clin Invest. 2003 Jun;33(6):493-9
pubmed: 12795646
Drug Metab Dispos. 2003 Dec;31(12):1520-5
pubmed: 14625348
Curr Drug Metab. 2004 Jun;5(3):235-43
pubmed: 15180493
Clin Pharmacokinet. 2005;44(1):33-60
pubmed: 15634031
Br J Clin Pharmacol. 2005 Apr;59(4):440-6
pubmed: 15801939
J Clin Invest. 2005 May;115(5):1111-9
pubmed: 15864338
Br J Clin Pharmacol. 2005 Jul;60(1):103-6
pubmed: 15963101
Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):57-61
pubmed: 15987645
Nat Rev Drug Discov. 2005 Oct;4(10):825-33
pubmed: 16224454
Annu Rev Pharmacol Toxicol. 2006;46:123-49
pubmed: 16402901
Drug Metab Dispos. 2006 May;34(5):880-6
pubmed: 16467132
Eur J Pharm Sci. 2006 May;28(1-2):51-8
pubmed: 16488120
J Pharmacol Exp Ther. 2006 Sep;318(3):1220-9
pubmed: 16763093
Eur J Pharm Sci. 2006 Nov;29(3-4):269-77
pubmed: 16822659
Drug Metab Dispos. 2006 Nov;34(11):1793-7
pubmed: 16896065
Pharmacogenet Genomics. 2007 Sep;17(9):731-42
pubmed: 17700362
Life Sci. 2007 Aug 23;81(11):924-32
pubmed: 17764701
Curr Drug Metab. 2008 Feb;9(2):122-8
pubmed: 18288954
Curr Drug Metab. 2008 Feb;9(2):129-43
pubmed: 18288955
Drug Metab Dispos. 2008 Jun;36(6):1039-45
pubmed: 18332081
Expert Opin Drug Metab Toxicol. 2008 May;4(5):529-44
pubmed: 18484913
Diabetes Care. 2009 Jan;32(1):193-203
pubmed: 18945920
Clin Pharmacol Ther. 2009 Apr;85(4):434-8
pubmed: 19212314
Clin Pharmacol Ther. 2009 Apr;85(4):387-93
pubmed: 19212316
J Clin Endocrinol Metab. 2009 Sep;94(9):3171-82
pubmed: 19509100
Drug Metab Rev. 2009;41(2):89-295
pubmed: 19514967
Proc West Pharmacol Soc. 2008;51:5-10
pubmed: 19544664
IUBMB Life. 2009 Oct;61(10):954-60
pubmed: 19787709
Biopharm Drug Dispos. 2009 Dec;30(9):532-41
pubmed: 19862765
Drug Metab Dispos. 2010 Feb;38(2):347-56
pubmed: 19923256
Xenobiotica. 2009 Dec;39(12):889-902
pubmed: 19925381
Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43
pubmed: 19934256
Xenobiotica. 2010 Apr;40(4):282-90
pubmed: 20163193
Drug Metab Dispos. 2010 May;38(5):817-23
pubmed: 20164111
Curr Drug Metab. 2010 Jan;11(1):4-84
pubmed: 20302566
Genome Res. 2010 Aug;20(8):1020-36
pubmed: 20538623
Drug Metab Dispos. 2010 Dec;38(12):2252-8
pubmed: 20736321
Curr Opin Mol Ther. 2010 Dec;12(6):695-702
pubmed: 21154161
Curr Drug Metab. 2010 Nov;11(9):793-805
pubmed: 21189138
Nat Rev Immunol. 2011 Feb;11(2):98-107
pubmed: 21233852
Br J Pharmacol. 2011 Jul;163(5):937-47
pubmed: 21323901
Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1083-100
pubmed: 21619472
Life Sci. 2011 Jul 4;89(1-2):57-64
pubmed: 21620874
Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):63-71
pubmed: 21742052
Pharmacogenomics. 2011 Aug;12(8):1161-91
pubmed: 21843065
PLoS One. 2011;6(8):e23506
pubmed: 21858147
Diab Vasc Dis Res. 2011 Oct;8(4):245-53
pubmed: 21933840
Diabetes Obes Metab. 2012 Mar;14(3):228-33
pubmed: 21958121
Life Sci. 2011 Dec 5;89(23-24):834-8
pubmed: 21983297
Biochem Pharmacol. 2012 Jan 15;83(2):279-85
pubmed: 22062654
Chem Biol Interact. 2012 Feb 5;195(3):173-9
pubmed: 22244987
Biochem Pharmacol. 2012 Jul 1;84(1):104-12
pubmed: 22484315
Expert Opin Drug Metab Toxicol. 2012 Dec;8(12):1549-63
pubmed: 23153186
J Pharmacol Exp Ther. 1990 Apr;253(1):387-94
pubmed: 2329521
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Endocrinology. 2013 Aug;154(8):2843-56
pubmed: 23696562
Drug Metab Rev. 2013 Aug;45(3):311-52
pubmed: 23865864
Mol Pharm. 2014 Oct 6;11(10):3547-55
pubmed: 25158075
J Pharm Biomed Anal. 2014 Nov;100:393-401
pubmed: 25218440
Am J Physiol Endocrinol Metab. 2015 Feb 15;308(4):E270-82
pubmed: 25389363
Am J Physiol Endocrinol Metab. 2015 Jan 15;308(2):E97-E110
pubmed: 25389366
Pharmacol Res Perspect. 2014 Dec;2(6):e00082
pubmed: 25505621
Drug Metab Dispos. 2015 Jul;43(7):1019-27
pubmed: 25904761
Drug Metab Dispos. 2016 Aug;44(8):1184-92
pubmed: 27217490
Acta Pharm Sin B. 2016 Sep;6(5):374-383
pubmed: 27709006
Sci Rep. 2017 Apr 25;7:46743
pubmed: 28440284
Pharmaceutics. 2017 Sep 26;9(4):null
pubmed: 28954402
BMJ Open. 2018 Feb 8;8(2):e020922
pubmed: 29439084
Xenobiotica. 2019 Feb;49(2):187-199
pubmed: 29448869
Br J Clin Pharmacol. 2019 Jun;85(6):1367-1377
pubmed: 30817016
Clin Pharmacol Ther. 2019 May 17;:null
pubmed: 31099895
J Pharm Biomed Anal. 2019 Sep 5;173:96-107
pubmed: 31125949
Gastroenterology. 1985 Feb;88(2):458-67
pubmed: 3965334
J Pharmacol Exp Ther. 1994 Jul;270(1):414-23
pubmed: 8035341
Clin Pharmacol Ther. 1996 May;59(5):491-502
pubmed: 8646820
Clin Pharmacol Ther. 1996 Jul;60(1):14-24
pubmed: 8689807
Mol Pharmacol. 1997 Jun;51(6):931-43
pubmed: 9187259
Drug Metab Rev. 1997 Nov;29(4):1129-88
pubmed: 9421688

Auteurs

Sophie Gravel (S)

Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada.
CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada.
ORCID: 0000-0002-1946-3414

Benoit Panzini (B)

CHUM-Centre Hospitalier de l'Université de Montréal, Department of Gastroenterology, Montreal, QC H2X 0A9, Canada.
Faculty of Medicine, Université de Montréal, Montreal, QC H3C 3J7, Canada.

Francois Belanger (F)

Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada.

Jacques Turgeon (J)

Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada.
CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada.

Veronique Michaud (V)

Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada. vmichaud@trhc.com.
CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada. vmichaud@trhc.com.
ORCID: 0000-0002-1399-6447

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs d'anions › Transporteurs d'anions organiques › Transporteurs d'anions organiques ATP-dépendants › Sous-famille B de transporteurs à cassette liant l'ATP › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Transporteurs ABC › Sous-famille G des transporteurs à cassette liant l'ATP › Membre-2 de la sous-famille G des transporteurs à cassette liant l'ATP › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Transporteurs ABC › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Carboxylic ester hydrolases › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Système digestif › Tube digestif › Tube digestif supérieur › Duodénum › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs d'anions › Transporteurs d'anions organiques › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Projets pilotes › A Pilot Study towards the Impact of Type 2...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › A Pilot Study towards the Impact of Type 2...